Olympus Recalls High Flow Insufflation Units Over Software-Related Overpressure Risk

Source: FDA · United States

Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Olympus Corporation of the Americas is recalling 744 UHI-2 High Flow Insufflation Units due to a software defect that may cause dangerous overpressure during surgery.

What this FDA recall tells you, and what most readers miss

This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, MedicalDevices.

What Happened

Olympus Corporation of the Americas has initiated a voluntary recall of its High Flow Insufflation Units, Model UHI-2. The recall was triggered by a defect in the device's software algorithm, which may cause the unit to create overpressure events during medical procedures. This recall has been classified as Class I by the FDA, indicating a high level of severity.

Which Products Are Affected

The recall impacts the following medical device:

  • Product Name: Olympus High Flow Insufflation Unit
  • Model Number: UHI-2
  • Quantity: 744 units
  • Affected Serial Numbers: All serial numbers are included in this recall.
  • Geographic Scope: These units were distributed nationwide across the United States.

The device is used for the insufflation of the abdominal cavity, as well as automatic suction and smoke evacuation to facilitate laparoscopic observation and treatment.

What You Should Do

Olympus began notifying customers of the issue via a formal letter on January 16, 2026. Healthcare facilities and providers in possession of these units should follow the specific guidance provided in the firm's notification. For additional information or inquiries regarding the recall process, the recalling firm can be contacted at their headquarters:

Olympus Corporation of the Americas 3500 Corporate Pkwy Center Valley, PA 18034-8229

Why This Matters

This is a Class I recall, the most serious classification, because the software issue poses a significant risk. Overpressure in the abdominal cavity during laparoscopic surgery can lead to serious patient complications or injury.

Source

Information provided by the FDA under recall number Z-1353-2026.

Original source: FDA Official Notice ↗

All FDA Recalls →

Frequently Asked Questions

Common questions about this FDA recall.

What is this FDA recall about?
Olympus Corporation of the Americas is recalling 744 UHI-2 High Flow Insufflation Units due to a software defect that may cause dangerous overpressure during surgery.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "high" severity. Take precautions and monitor for updates.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more FDA Recalls updates?
Browse the full FDA Recalls feed on Areazine at areazine.com/recalls/fda/ for the latest updates from FDA and other agencies.